Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed, Inc. (Symbol: INSM) is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a mission to transform the lives of patients with serious and rare diseases. The company is committed to developing and bringing to market therapies that significantly improve patient lives, focusing on the entire patient journey from diagnosis and treatment to daily living.
Insmed's flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. ARIKAYCE, utilizing Insmed's proprietary PULMOVANCE® liposomal technology, delivers amikacin directly to the lungs, reducing systemic exposure and associated toxicities. It is administered using the Lamira® Nebulizer System developed by PARI Pharma GmbH, known for its efficiency and portability.
The company’s clinical pipeline includes multiple promising candidates. Notable among them is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being developed for treating non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases. Another significant pipeline product is TPIP (Treprostinil Palmitil Inhalation Powder), an inhaled formulation being evaluated for pulmonary arterial hypertension and other serious pulmonary disorders.
Insmed has demonstrated robust financial performance, with significant revenue growth driven by ARIKAYCE. The company continues to invest heavily in research and development, with plans to expand its product portfolio and market reach globally.
Insmed's strategic partnerships and collaborations play a crucial role in advancing its mission. These include collaborations with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB for utilizing their expertise in respiratory diseases.
Recent updates include positive financial results for the third quarter of 2023, robust revenue growth from ARIKAYCE, and significant progress in clinical trials. Noteworthy are the topline results from the Phase 3 ASPEN study for Brensocatib, indicating its potential as a first-in-class treatment. Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib by late 2024, aiming for a potential launch in 2025.
The company is also advancing its early-stage research engine, exploring innovative technologies such as artificial intelligence-driven protein engineering and gene therapy, positioning itself at the forefront of biopharmaceutical innovation.
Insmed (INSM) reported strong preliminary results for 2024, with ARIKAYCE global net product sales reaching approximately $363.7 million, exceeding guidance and showing 19% year-over-year growth. The company projects 2025 ARIKAYCE revenues between $405-425 million.
Key developments include: submission of NDA for Brensocatib in bronchiectasis with anticipated U.S. launch in Q3 2025; completion of enrollment in TPIP Phase 2 study for PAH with topline data expected mid-2025; full enrollment of Phase 3 ENCORE trial for ARIKAYCE with topline data expected in Q1 2026; and FDA clearance for INS1201, their first gene therapy for DMD, with first patient dosing planned for H1 2025.
Regional ARIKAYCE sales growth: U.S. (+14%) at $254.8M, Japan (+33%) at $87.7M, and Europe (+39%) at $21.2M.
Insmed Incorporated (INSM) has announced the granting of inducement awards to 19 new employees. The awards, approved by Insmed's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), were made as material inducement for employment.
The employees received options on January 2, 2025, to purchase a total of 65,930 shares of Insmed common stock at an exercise price of $69.95 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The options come with a 10-year term and a four-year vesting schedule, with 25% vesting after the first year and 12.5% vesting every six months thereafter until the fourth anniversary, contingent on continued employment.
Insmed (Nasdaq: INSM) has announced its management team will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET.
The event will be accessible via webcast through the investor relations section of Insmed's website at www.insmed.com. The webcast recording will remain available for 30 days after the live presentation concludes.
Insmed (INSM) has granted inducement awards to 30 new employees as part of their employment agreements. The awards consist of options to purchase a total of 64,240 shares of Insmed common stock at an exercise price of $72.42 per share, which was the closing price on the Nasdaq Global Select Market on the grant date of December 2, 2024.
The stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after the first year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment with Insmed.
Insmed (Nasdaq: INSM) has announced its participation in two major investor conferences in December 2024. The company will present at the Evercore ISI HealthCONx Conference in Coral Gables, Florida, on December 4 at 11:15 a.m. ET, and at the Nasdaq 51st Investor Conference in London on December 11 at 10:30 a.m. GT (5:30 a.m. ET). Both presentations will be available via webcast on the company's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM) has granted inducement awards to 27 new employees as of November 1, 2024. The awards consist of options to purchase a total of 66,740 shares of common stock at an exercise price of $68.32 per share, which was the closing price on Nasdaq Global Select Market on the grant date. These stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after one year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment.
Insmed (Nasdaq: INSM) has announced its participation in four major healthcare investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), UBS Global Healthcare Conference in Rancho Palos Verdes (Nov. 12), Wolfe Research Healthcare Conference in New York (Nov. 20), and Jefferies London Healthcare Conference in London (Nov. 21). All presentations will be webcast live through Insmed's investor relations website and archived for 30 days after the events.
Insmed (INSM) reported Q3 2024 financial results with ARIKAYCE revenue of $93.4 million, showing 18% growth year-over-year. The company maintained its 2024 global ARIKAYCE revenue guidance of $340-360 million. The quarter ended with approximately $1.5 billion in cash and equivalents. Key developments include the planned NDA submission for Brensocatib in Q4 2024 with potential U.S. launch in mid-2025, and a renegotiated term loan providing an additional $150 million. The company reported a net loss of $220.5 million ($1.27 per share) compared to $158.9 million ($1.11 per share) in Q3 2023.
Insmed (Nasdaq:INSM) has secured the #1 position in Science's 2024 Top Employers Survey for the fourth consecutive year. The survey, which gathered nearly 6,500 responses primarily from North America (65%), Europe (19%), and Asia/Pacific Rim (11%), evaluates companies in biotechnology and pharmaceutical industries.
The company stood out for its innovative leadership, respect for employees, social responsibility, and employee loyalty. With over 1,200 employees worldwide, Insmed has demonstrated strength in commercial and pipeline programs while maintaining its commitment to transforming patients' lives with serious diseases. The recognition highlights Insmed's distinctive culture and continued global expansion.
Insmed (INSM) held its third annual Global Day of Good, involving over 1,000 employees in volunteer activities across the U.S., Europe, and Japan. The company-wide service day supported more than 40 organizations globally, focusing on improving health, education, and human services. Activities included preparing kits for pediatric cancer patients, building playhouses, revitalizing community centers, packing food for pantries, sorting clothing donations, and translating children's books. Both remote and in-person volunteering options were available to ensure all employees could participate.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
What is Insmed's primary mission?
What is ARIKAYCE?
What are Brensocatib and TPIP?
Where is Insmed headquartered?
What are Insmed's recent financial highlights?
What are the strategic partnerships of Insmed?
What are the latest developments in Insmed's clinical trials?
What is Insmed's approach to early-stage research?
What is the Lamira® Nebulizer System?
When does Insmed plan to file an NDA for Brensocatib?
